Stay updated on Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page changed from a 403 error screen to the ClinicalTrials.gov record for a Phase 2 metastatic melanoma study, including its eligibility criteria, treatment arms, outcomes, and study documents.SummaryDifference55%

- Check17 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedThe clinical trial record for a Phase 2 study of nivolumab with relatlimab or ipilimumab in metastatic melanoma is displayed, including its terminated status due to loss of funding and its study details. The record also includes results-related measures, eligibility criteria, and a study protocol document.SummaryDifference58%

- Check31 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 while the page remained a 403 error page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden error with a generic header/footer, replacing the usual study details and indicating the record is temporarily inaccessible rather than content updates.SummaryDifference19%

Stay in the know with updates to Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.